Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib Journal Article

   

Authors:	Hellmann, M. D.; Reva, B.; Yu, H.; Rusch, V. W.; Rizvi, N. A.; Kris, M. G.; Arcila, M. E.
Article Title:	Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib
Keywords:	treatment response; cancer surgery; gene mutation; case report; erlotinib; cancer staging; polymerase chain reaction; mass spectrometry; allele; epidermal growth factor receptor; genotype; smoking; in vivo study; wild type; lung metastasis; lung adenocarcinoma; hydrogen bond; protein structure; drug sensitivity; mutant; locked nucleic acid; human; priority journal; article
Journal Title:	Journal of Thoracic Oncology
Volume:	9
Issue:	10
ISSN:	1556-0864
Publisher:	Elsevier Inc.
Date Published:	2014-10-01
Start Page:	e73
End Page:	e74
Language:	English
DOI:	10.1097/jto.0000000000000221
PROVIDER:	scopus
PUBMED:	25521405
PMCID:	PMC4655969
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84925813420&partnerID=40&md5=ef55eba47a65bf31436b543f6b56ad4f
Notes:	Export Date: 4 May 2015 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/72285